Inclusion Criteria:  Female aged 18 - 70 years old; The histopathological confirm of invasive breast cancer; HER-2 positive: immuno-histochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) confirmed amplification of erbb2 gene; Tumor must be ≤ 2cm in greatest dimension, negative axillary lymph node or with micrometastasis (axillary nodes with tumor clusters ≤ 0.2cm); No more than 90 days from the patient's most recent breast surgery for this breast cancer; Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1; Adequate bone marrow function: neutrophil ≥ 1500/mm^3, hemoglobin ≥ 9 g/dl, and platelets ≥ 100,000/mm^3; Adequate liver and renal function: creatinine ≤ 1.5 folds of the upper limit of normal value; aspartate aminotransferase and alanine aminotransferase ≤ 1.5 folds of the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2 folds of the upper limit of normal value for patient with Gilbert 's syndrome; Left ventricular ejection fraction (LVEF) ≥ 50%; Willing and able to sign informed consent.  Exclusion Criteria:  Any of the following due to teratogenic potential of chemotherapy: pregnant women, nursing women, women of childbearing potential who are unwilling to employ adequate contraception; Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes; History of prior chemotherapy in the past 5 years; History of prior trastuzumab therapy; Patients with a history of previous invasive breast cancer; Active, unresolved infection; Prior history of any other malignancy in the past 5 years, except for early stage tumors of the skin or cervix treated with curative intent; Can not tolerate or be allergic to chemotherapy, anti-HER-2 therapy or pharmaceutical materials such as benzyl alcohol; ≥ grade 2 neuropathy; Active cardiac disease: Any prior myocardial infarction (asymptomatic changes on EKG suggestive of old myocardial infarction is not an exclusion); Documented congestive heart failure (CHF); Current use of any therapy specifically for CHF; Current uncontrolled hypertension (diastolic >100 mmHg or systolic > 200 mmHg); Clinically significant pericardial effusion; The antibody of hepatitis C virus, HIV or Treponema pallidum positive; HBsAg positive and hepatitis B virus DNA in peripheral blood ≥ 10^3 copy/mL； Enrollment on other Investigational studies within 30 days; Not allowed by the investigators.